Quince Therapeutics (QNCX) Competitors $1.68 -0.01 (-0.59%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.65 -0.03 (-1.79%) As of 08/1/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNCX vs. RCKT, INBX, ABEO, AVIR, ALT, ALLO, ADCT, NGNE, CAPR, and OLMAShould you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Rocket Pharmaceuticals (RCKT), Inhibrx Biosciences (INBX), Abeona Therapeutics (ABEO), Atea Pharmaceuticals (AVIR), Altimmune (ALT), Allogene Therapeutics (ALLO), ADC Therapeutics (ADCT), Neurogene (NGNE), Capricor Therapeutics (CAPR), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry. Quince Therapeutics vs. Its Competitors Rocket Pharmaceuticals Inhibrx Biosciences Abeona Therapeutics Atea Pharmaceuticals Altimmune Allogene Therapeutics ADC Therapeutics Neurogene Capricor Therapeutics Olema Pharmaceuticals Quince Therapeutics (NASDAQ:QNCX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk. Does the media prefer QNCX or RCKT? In the previous week, Rocket Pharmaceuticals had 40 more articles in the media than Quince Therapeutics. MarketBeat recorded 41 mentions for Rocket Pharmaceuticals and 1 mentions for Quince Therapeutics. Rocket Pharmaceuticals' average media sentiment score of 0.09 beat Quince Therapeutics' score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Quince Therapeutics Neutral Rocket Pharmaceuticals Neutral Which has more volatility and risk, QNCX or RCKT? Quince Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Which has preferable valuation & earnings, QNCX or RCKT? Quince Therapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$56.83M-$1.39-1.21Rocket PharmaceuticalsN/AN/A-$258.75M-$2.63-1.14 Do analysts prefer QNCX or RCKT? Quince Therapeutics currently has a consensus target price of $8.00, indicating a potential upside of 376.19%. Rocket Pharmaceuticals has a consensus target price of $17.87, indicating a potential upside of 497.55%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Quince Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Rocket Pharmaceuticals 1 Sell rating(s) 9 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.35 Is QNCX or RCKT more profitable? Rocket Pharmaceuticals' return on equity of -64.92% beat Quince Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -117.52% -34.22% Rocket Pharmaceuticals N/A -64.92%-56.13% Do institutionals & insiders have more ownership in QNCX or RCKT? 30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 20.3% of Quince Therapeutics shares are held by company insiders. Comparatively, 24.8% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryRocket Pharmaceuticals beats Quince Therapeutics on 8 of the 14 factors compared between the two stocks. Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNCX vs. The Competition Export to ExcelMetricQuince TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.63M$3.00B$5.47B$9.53BDividend YieldN/A2.43%4.74%4.08%P/E Ratio-1.2117.6228.6723.80Price / SalesN/A268.97422.2688.08Price / CashN/A41.9535.4557.96Price / Book2.438.508.275.55Net Income-$56.83M-$55.06M$3.24B$259.03M7 Day Performance-9.19%-3.98%-3.63%-4.56%1 Month Performance5.00%9.59%4.40%4.49%1 Year Performance140.00%6.72%25.97%18.05% Quince Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNCXQuince Therapeutics2.2568 of 5 stars$1.68-0.6%$8.00+376.2%+125.9%$90.63MN/A-1.2160Short Interest ↑RCKTRocket Pharmaceuticals4.8338 of 5 stars$3.11-1.0%$17.87+474.5%-86.5%$335.31MN/A-1.18240Trending NewsUpcoming EarningsINBXInhibrx Biosciences1.3386 of 5 stars$24.57+6.5%N/A+48.2%$334.10M$200K0.21166ABEOAbeona Therapeutics3.5155 of 5 stars$6.62+1.4%$19.25+190.8%+34.9%$334.05M$3.50M-5.2190AVIRAtea Pharmaceuticals1.6726 of 5 stars$3.79-2.8%$6.00+58.3%-4.4%$333.76MN/A-2.3070News CoverageUpcoming EarningsALTAltimmune2.2484 of 5 stars$4.03-1.2%$18.20+351.6%-40.7%$330.92M$20K-3.2050Upcoming EarningsALLOAllogene Therapeutics2.9924 of 5 stars$1.47-2.0%$8.44+474.5%-60.6%$328.10M$20K-1.20310News CoverageUpcoming EarningsADCTADC Therapeutics1.3823 of 5 stars$3.13-4.7%$7.75+148.0%-11.4%$325.30M$70.84M-2.16310News CoverageUpcoming EarningsNGNENeurogene2.8011 of 5 stars$21.68-4.6%$46.17+112.9%-46.2%$324.03M$930K-4.9890News CoveragePositive NewsUpcoming EarningsCAPRCapricor Therapeutics3.444 of 5 stars$6.79-3.8%$22.56+232.2%+102.0%$322.48M$22.27M-4.78101Trending NewsUpcoming EarningsOLMAOlema Pharmaceuticals2.074 of 5 stars$4.83+2.5%$24.50+407.2%-67.6%$322.26MN/A-2.4070Positive NewsUpcoming Earnings Related Companies and Tools Related Companies Rocket Pharmaceuticals Alternatives Inhibrx Biosciences Alternatives Abeona Therapeutics Alternatives Atea Pharmaceuticals Alternatives Altimmune Alternatives Allogene Therapeutics Alternatives ADC Therapeutics Alternatives Neurogene Alternatives Capricor Therapeutics Alternatives Olema Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNCX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
